PDGF Biocompatible Matrix for Osteodistraction Bone Consolidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Osteodistraction procedures face challenges with delayed consolidation and reduced mineral content and tensile strength of regenerated bone, leading to increased complications such as infection and prolonged recovery times.
Innovation Solution
A composition comprising platelet-derived growth factor (PDGF) in a biocompatible matrix, specifically calcium phosphate or collagen, is applied during or after bone distraction to stimulate osteogenesis, accelerating the consolidation phase and enhancing bone regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of moving object
If distraction osteogenesis is performed to bridge large bony defects, then bone lengthening and defect bridging are achieved, but the regenerated bone has reduced mineral content and tensile strength
Solution Approach 1:
The patent introduces platelet-derived growth factor (PDGF) as an intermediary substance to mediate the bone regeneration process. PDGF is applied to the distraction site to stimulate osteoblast proliferation and bone matrix formation, thereby improving the quality and strength of regenerated bone while maintaining the bone lengthening effect
Solution Approach 2:
The patent modifies the biochemical parameters of the regeneration environment by introducing growth factors (PDGF) and potentially other biological agents. This changes the biological activity and composition of the regenerating tissue, leading to improved mineral content and tensile strength of the new bone
2Volume of moving object
If distraction osteogenesis is performed to bridge large bony defects, then bone lengthening is achieved, but mineral content of regenerated bone is reduced
Solution Approach 1:
PDGF serves as a biochemical intermediary that stimulates osteoblast activity and bone matrix production. The growth factor enhances the mineralization process by promoting osteoblast differentiation and bone matrix formation, thereby increasing the mineral content of regenerated bone
Solution Approach 2:
The patent alters the biochemical composition and mineralization parameters of the regenerating bone by introducing growth factors. This changes the rate and extent of mineral deposition, resulting in regenerated bone with improved mineral content
3Volume of moving object
If conventional distraction osteogenesis is used, then bone bridging is achieved, but consolidation phase is prolonged
Solution Approach 1:
The patent applies PDGF during the distraction phase as a preliminary action to prepare and accelerate the consolidation process. By introducing growth factors early in the procedure, the bone regeneration and consolidation phases are expedited, reducing the overall treatment time
Solution Approach 2:
PDGF acts as a biochemical mediator that accelerates the transition from distraction to consolidation by stimulating osteoblast activity and bone matrix formation, thereby shortening the consolidation period
4Volume of moving object
If distraction osteogenesis is performed, then large bony defects are bridged, but risk of infection and complications increases
Solution Approach 1:
PDGF serves as a protective intermediary by promoting rapid bone formation and consolidation, which creates a more stable and resistant structure that is less susceptible to infection and other complications
Data Source
AI summary
The present invention relates to compositions and methods for use in osteodistraction procedures. In one embodiment, a method of stimulating osteogenesis during and/or following bone distraction comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of bone distraction.